Enfortumab Vedotin–Pembrolizumab in Advanced Urothelial Cancer | NEJM

Among patients with advanced urothelial cancer, 5-year survival with first-line platinum-based chemotherapy is relatively low. Enfortumab vedotin plus pembrolizumab may improve outcomes.

Research findings are summarized in a new Quick Take video.

#oncology #urology #clinicaltrials #nejm